Opioid analgesics often lose their effectiveness over time because their main target, the mu‑opioid receptor (MOR), becomes less responsive, especially in chronic pain. A natural molecule in the body, N‑oleoyldopamine (OLDA), which also activates TRPV1 receptors involved in pain sensation, can protect these receptors and thereby help maintain the analgesic effect of opioids. In the rat spinal cord, prolonged exposure to the opioid DAMGO usually leads to MOR “desensitization,” so that these receptors stop dampening pain signals, but OLDA acting via TRPV1 prevents this loss of effect without disrupting normal neural activity. In a neuropathic pain model after nerve injury, OLDA becomes even more effective due to the increased sensitivity of pain pathways and TRPV1 receptors. In in vivo experiments, OLDA also restores the analgesic effect of DAMGO under conditions in which neuro-inflammatory signals would normally suppress MOR function. These findings suggest that targeting OLDA–TRPV1 pathways could represent a new strategy to preserve the analgesic efficacy of opioids and potentially limit dose escalation and adverse effects in patients with chronic pain.
Heles M, Vasconcelos D, Palecek J. Endogenous TRPV1 agonist OLDA prevents mu-opioid receptor desensitization and preserves analgesia in sensitized nociceptive circuits. Neuropharmacology. 2026 Apr 15;294:110975. doi: 10.1016/j.neuropharm.2026.110975. PMID: 41990968.
